Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Cadonilimab in Renal Cell Carcinoma: NCT06138496 Clinical Landscape Report 2026
16 October 2026
NCT06138496 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CTX-8371 in Uveal Melanoma: NCT06150664 Clinical Landscape Report 2026
16 October 2026
NCT06150664 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab biosimilar(Sandoz) in Melanoma: NCT06153238 Clinical Landscape Report 2026
16 October 2026
NCT06153238 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19 CAR-T (Shanghai Ming Ju Biotechnology ) in Diffuse Large B-Cell Lymphoma: NCT06149169 Clinical Landscape Report 2026
16 October 2026
NCT06149169 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Melanoma, Cutaneous Malignant: NCT06151847 Clinical Landscape Report 2026
16 October 2026
NCT06151847 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atorvastatin Calcium in Melanoma, Cutaneous Malignant: NCT06157099 Clinical Landscape Report 2026
16 October 2026
NCT06157099 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cabozantinib (s)-Malate in Ewing Sarcoma: NCT06156410 Clinical Landscape Report 2026
16 October 2026
NCT06156410 clinical landscape for Ewing Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DFP-13318 in Breast Feeding: NCT06162351 Clinical Landscape Report 2026
16 October 2026
NCT06162351 clinical landscape for Breast Feeding: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Budigalimab in Relapsed Solid Neoplasm: NCT06158958 Clinical Landscape Report 2026
16 October 2026
NCT06158958 clinical landscape for Relapsed Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etoposide in Diffuse large B-cell lymphoma recurrent: NCT06164327 Clinical Landscape Report 2026
16 October 2026
NCT06164327 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Disitamab Vedotin in HER2-Low Breast Carcinoma: NCT06157892 Clinical Landscape Report 2026
16 October 2026
NCT06157892 clinical landscape for HER2-Low Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT06165900 Clinical Landscape Report 2026
16 October 2026
NCT06165900 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.